Sanofi: Zaltrap obtains approval in Europe

BUY, Fair Value EUR84 (+21%)

News published on February Tuesday 5, 2013
Share on
Although this comes as no a major surprise following the positive recommendation received last November, Sanofi has announced that the European Commission has approved Zaltrap (aflibercept) this morning. The compound is an anti-angiogenesis compound developed in partnership with Regeneron and indicated in second-line treatment of colorectal cancer in combination with chemotherapy.


Full report available to subscribers
Please contact marketing@bryangarnier.fr

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities